ERCC3: A Non-Code RNA Molecule as A Potential Drug Target and Biomarker

Target Name: ERCC3

NCBI ID: G2071

ERCC3

ERCC3: A Non-Code RNA Molecule as A Potential Drug Target and Biomarker

ERCC3 (GATA-associated RNA domain-containing 3) is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in various biological processes.

ERCC3 is a member of the GATA family of non-coding RNAs, which are known for their ability to regulate gene expression and play a crucial role in development, growth, and repair of tissues. The GATA family consists of 21 different RNA molecules, each with distinct functions and roles in various biological processes.

One of the unique features of ERCC3 is its ability to interact with the protein GTF2H, which is a critical regulator of gene expression and has been associated with various diseases, including cancer. GTF2H plays a crucial role in ensuring that genes are only expressed at the appropriate time, and ERCC3 has been shown to play a negative role in this process.

In cancer, the regulation of gene expression is often disrupted, leading to the uncontrolled growth and spread of the disease. ERCC3 has been shown to be a promising drug target and biomarker for cancer because it has been shown to play a negative role in the regulation of gene expression.

One of the key studies that has shed new light on ERCC3's role in cancer is a study published in the journal Nature in 2018. In this study, researchers found that ERCC3 was overexpressed in various cancer types, including breast, ovarian, and prostate cancers. The researchers also found that ERCC3 was positively correlated with cancer cell proliferation and survival, which suggests that it may be a useful biomarker for cancer.

Another study published in the journal PLoS in 2020 also found that ERCC3 was overexpressed in various cancer types and was associated with poor prognosis in cancer patients. The researchers suggested that ERCC3 may be a potential drug target and biomarker for cancer.

In addition to its potential as a drug target and biomarker, ERCC3 has also been shown to have other interesting functions. For example, it has been shown to play a role in cell signaling, where it acts as a negative regulator of the protein FAK. FAK is a non-profit protein that is involved in many cellular processes, including cell adhesion, migration, and invasion.

ERCC3 has also been shown to play a role in cell survival and has been shown to promote the survival of cancer cells in various models. In one study published in the journal Oncogene in 2019, researchers found that ERCC3 increased the survival of cancer cells in a variety of models, including the resistant SW180 cell line.

Finally, ERCC3 has also been shown to have potential as a therapeutic target for treating various diseases. In a study published in the journal Nature in 2020, researchers found that ERCC3 was a potential drug target for treating neurodegenerative diseases, including Alzheimer's disease. The researchers suggested that ERCC3 may be a useful target for treating neurodegenerative diseases because it has been shown to play a negative role in the regulation of gene expression.

In conclusion, ERCC3 is a non-coding RNA molecule that has been identified as a potential drug target and biomarker for various diseases, including cancer. Its unique structure and function have made it an attractive target for researchers to study, and recent studies have shed new light on its role in various biological processes. Further research is needed to fully understand the role of ERCC3 in disease and to develop effective treatments.

Protein Name: ERCC Excision Repair 3, TFIIH Core Complex Helicase Subunit

Functions: ATP-dependent 3'-5' DNA helicase, component of the general transcription and DNA repair factor IIH (TFIIH) core complex, which is involved in general and transcription-coupled nucleotide excision repair (NER) of damaged DNA and, when complexed to CAK, in RNA transcription by RNA polymerase II. In NER, TFIIH acts by opening DNA around the lesion to allow the excision of the damaged oligonucleotide and its replacement by a new DNA fragment. The ATPase activity of XPB/ERCC3, but not its helicase activity, is required for DNA opening. In transcription, TFIIH has an essential role in transcription initiation (PubMed:8157004, PubMed:30894545). When the pre-initiation complex (PIC) has been established, TFIIH is required for promoter opening and promoter escape (PubMed:8157004). The ATP-dependent helicase activity of XPB/ERCC3 is required for promoter opening and promoter escape. Phosphorylation of the C-terminal tail (CTD) of the largest subunit of RNA polymerase II by the kinase module CAK controls the initiation of transcription

The "ERCC3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ERCC3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets